FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053896303> ?p ?o ?g. }

• W2053896303 endingPage "2225" @default.
• W2053896303 startingPage "2223" @default.
• W2053896303 abstract "A diagnostic test would be useful to help eliminate the associated morbidity and mortality after full-dose rechallenge with abacavir in patients with suspected hypersensitivity. We describe seven patients with syndromes compatible with abacavir hypersensitivity who had positive patch tests. Immunohistochemistry on skin biopsies from the acute prospectively identified patients with rash (n = 3) matched those from positive-patch patients (n = 7), suggesting an identical pathophysiological process. No patients developed systemic symptoms or signs during patch testing. Abacavir is a nucleoside analogue used in combination with other antiretroviral drugs for the treatment of HIV. Approximately 2–5% of patients starting abacavir will experience a hypersensitivity syndrome, most commonly characterized by combinations of fever, rash, malaise, nausea, vomiting and diarrhoea. Severe reactions such as shock and even death have been described with full dose rechallenge after the occurrence of the hypersensitivity syndrome [1]. Patch testing is an ‘in-vivo’ test that involves the application of dilute, non-irritating concentrations of the substance or drug in a vehicle such as petrolatum to the surface of the skin. There is significant experience with patch testing for the diagnosis of T cell-mediated processes such as allergic contact dermatitis. Patch testing is simple and inexpensive to perform. Currently there is limited information as to the use of patch testing for other potentially cell-mediated processes such as drug reactions [2]. The rationale for use in these reactions is supported by the potential metabolism of the parent drug to reactive metabolite in skin and the presence of resident CD8 cells from skin biopsies of patients with acute drug-induced hypersensitivity syndromes [3]. We describe seven patients who developed positive patch tests to abacavir within 4 months of a presumed abacavir hypersensitivity reaction (Table 1, Fig. 1). One patient (case 6) was identified 33 months after the initial reaction. Four patients were identified prospectively at the time of the reaction, and three were identified retrospectively after the initial reaction. All patients met a minimum case definition of probable abacavir hypersensitivity syndrome, defined as either having at least two intensifying symptoms of rash, fever, gastrointestinal complaints, headache and resolution within 24 h of stopping the drug without an alternative explanation or a positive rechallenge to abacavir. Rash occurred in three out of four prospectively identified patients as part of the acute reaction, with immunohistochemistry documented (Table 1). Patients and HIV-negative controls had one patch panel of 1% abacavir and 10% abacavir in a petrolatum base applied to the mid-back. All patches were taken off at 48 h. Reading took place at 48 and 96 h in cases 1 to 3. Cases 4 to 7 and four additional HIV-infected controls tolerating or known to have tolerated abacavir also had 0.1, 5, 15 and 25% abacavir added to the patch panel, with additional readings at 1, 24, 48 and 96 h. Two HIV-negative controls with no previous abacavir exposure and five HIV-positive controls with previous abacavir exposure matched for age, sex, race, CD4 cell count and viral load had negative patch tests at 48 and 96 h.Fig. 1.: Patch testing at 24 h illustrating dose reponse (case 5).Table 1: Clinical summary of patch test-positive patients.Patch testing was positive in seven patients with probable abacavir hypersensitivity and negative in seven controls. This may be an extremely useful diagnostic modality for identifying patients with true abacavir reactions. HIV patients are often started on multiple concurrent medications, making the implication of a single drug in a reaction difficult. The clinical diagnosis of abacavir hypersensitivity syndrome was further strengthened in our six out of seven patch test-positive patients by subsequent rechallenge and tolerance of of of other antiretroviral drugs that they were taking at the time of the initial reaction. The pathological concordance between the two biopsies and patch testing further strengthens this, and sheds light on the pathophysiology of the acute skin reaction and positive patch tests. The immunohistochemistry on the acute skin rash biopsies and patch biopsies are in fact identical to previously presented data on skin biopsies from patients with acute abacavir hypersensitivity syndrome [4]. The absence of B cell markers and the presence of HLA-DR in all of the biopsies suggests a primarily cell-mediated, T helper cell type 1 response. These preliminary results suggest that an inexpensive and safe procedure such as patch testing may be a useful adjunct to the clinical diagnosis of abacavir hypersensitivity syndrome. Cases 4 to 7 illustrates that patch testing can become positive within 24 h of applying the patch. It should be emphasized that this test is currently a research tool, and a negative patch test at this time cannot be interpreted as grounds for full-dose unsupervised rechallenge with abacavir. Case 6 illustrates that patch tests can be positive remote from the initial exposure. However, the exact time course of when the test becomes positive in relation to the hypersensitivity syndrome and the expected duration of positivity in these patients is currently unknown and is the subject of further investigation. Acknowledgements The authors would like to acknowledge GlaxoSmith Kline US, Research Triangle, NC, USA, and the Canadian Infectious Disease Society for their support of this study; Dr Rodney Miller, Propath Laboratories, Dallas TX, USA, who processed the skin biopsies; and Drs A. Rachlis, S. Walmsley and C. Kovacs for their contribution of patients." @default.
• W2053896303 created "2016-06-24" @default.
• W2053896303 creator A5000743912 @default.
• W2053896303 creator A5008411415 @default.
• W2053896303 creator A5027305090 @default.
• W2053896303 creator A5080985934 @default.
• W2053896303 date "2002-11-01" @default.
• W2053896303 modified "2023-10-15" @default.
• W2053896303 title "Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir" @default.
• W2053896303 cites W2023706681 @default.
• W2053896303 cites W2076661568 @default.
• W2053896303 doi "https://doi.org/10.1097/00002030-200211080-00017" @default.
• W2053896303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12409746" @default.
• W2053896303 hasPublicationYear "2002" @default.
• W2053896303 type Work @default.
• W2053896303 sameAs 2053896303 @default.
• W2053896303 citedByCount "134" @default.
• W2053896303 countsByYear W20538963032012 @default.
• W2053896303 countsByYear W20538963032013 @default.
• W2053896303 countsByYear W20538963032014 @default.
• W2053896303 countsByYear W20538963032015 @default.
• W2053896303 countsByYear W20538963032016 @default.
• W2053896303 countsByYear W20538963032017 @default.
• W2053896303 countsByYear W20538963032018 @default.
• W2053896303 countsByYear W20538963032019 @default.
• W2053896303 countsByYear W20538963032020 @default.
• W2053896303 countsByYear W20538963032021 @default.
• W2053896303 countsByYear W20538963032022 @default.
• W2053896303 countsByYear W20538963032023 @default.
• W2053896303 crossrefType "journal-article" @default.
• W2053896303 hasAuthorship W2053896303A5000743912 @default.
• W2053896303 hasAuthorship W2053896303A5008411415 @default.
• W2053896303 hasAuthorship W2053896303A5027305090 @default.
• W2053896303 hasAuthorship W2053896303A5080985934 @default.
• W2053896303 hasBestOaLocation W20538963031 @default.
• W2053896303 hasConcept C16005928 @default.
• W2053896303 hasConcept C203014093 @default.
• W2053896303 hasConcept C2522874641 @default.
• W2053896303 hasConcept C2777869810 @default.
• W2053896303 hasConcept C2778570526 @default.
• W2053896303 hasConcept C2779277585 @default.
• W2053896303 hasConcept C2779465607 @default.
• W2053896303 hasConcept C2780593183 @default.
• W2053896303 hasConcept C2780664588 @default.
• W2053896303 hasConcept C2909097316 @default.
• W2053896303 hasConcept C71924100 @default.
• W2053896303 hasConceptScore W2053896303C16005928 @default.
• W2053896303 hasConceptScore W2053896303C203014093 @default.
• W2053896303 hasConceptScore W2053896303C2522874641 @default.
• W2053896303 hasConceptScore W2053896303C2777869810 @default.
• W2053896303 hasConceptScore W2053896303C2778570526 @default.
• W2053896303 hasConceptScore W2053896303C2779277585 @default.
• W2053896303 hasConceptScore W2053896303C2779465607 @default.
• W2053896303 hasConceptScore W2053896303C2780593183 @default.
• W2053896303 hasConceptScore W2053896303C2780664588 @default.
• W2053896303 hasConceptScore W2053896303C2909097316 @default.
• W2053896303 hasConceptScore W2053896303C71924100 @default.
• W2053896303 hasIssue "16" @default.
• W2053896303 hasLocation W20538963031 @default.
• W2053896303 hasLocation W20538963032 @default.
• W2053896303 hasLocation W20538963033 @default.
• W2053896303 hasOpenAccess W2053896303 @default.
• W2053896303 hasPrimaryLocation W20538963031 @default.
• W2053896303 hasRelatedWork W2036037138 @default.
• W2053896303 hasRelatedWork W2053896303 @default.
• W2053896303 hasRelatedWork W2577179017 @default.
• W2053896303 hasRelatedWork W2585139052 @default.
• W2053896303 hasRelatedWork W2782736660 @default.
• W2053896303 hasRelatedWork W2971951663 @default.
• W2053896303 hasRelatedWork W3189834894 @default.
• W2053896303 hasRelatedWork W3196645532 @default.
• W2053896303 hasRelatedWork W4205335551 @default.
• W2053896303 hasRelatedWork W4237910206 @default.
• W2053896303 hasVolume "16" @default.
• W2053896303 isParatext "false" @default.
• W2053896303 isRetracted "false" @default.
• W2053896303 magId "2053896303" @default.
• W2053896303 workType "article" @default.